Reduced diffusing capacity of the lungs for carbon monoxide (DLco) reflects microvasculopathy in chronic thromboembolic ...
Effect of branched-chain amino acid metabolic interactions between HIBADH+ tumor cells and BCAT1+ macrophages on immunotherapy response in advanced NSCLC. Baseline DLCO 1.04 (0.99-1.1);p=0.1 1.04 ...
The diffusion capacity of the lung for carbon monoxide (DLCO) is used to measure the body's ability to transfer oxygen across the alveolar-capillary membrane. [1] Internists use this test to identify ...
Background—Pulmonary diffusing capacity for carbon monoxide (Dlco), alveolar capillary membrane diffusing capacity (Dm), and pulmonary capillary blood volume (Vc) are all significantly reduced after ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Impairment of lung diffusion capacity, which correlated ...
Researchers have found that patients who have idiopathic pulmonary arterial hypertension (IPAH) with a phenotype characterized by a smoking history and low diffusion capacity for carbon monoxide had ...
Additionally, the change in diffusion capacity (DLco), low-density lipoprotein, and high-sensitivity C-reactive protein were independently associated with the increasing evolution of AIx. The average ...
Extending the use of a continuous positive airway pressure (CPAP) treatment in premature infants by two weeks significantly increases lung volume and lung diffusion capacity, according to a new study.
CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback